In today's Pharmaceutical Executive Daily, Invivyd's chief scientific officer discusses a platform designed to predict future viral variants ahead of time, Bristol Myers Squibb expands its AI compute infrastructure with Nvidia to build what it calls the most powerful AI factory in life sciences, and FDA clears Consano Bio's IND for a non-opioid biologic targeting chronic sciatica.
FDA has cleared Consano Bio's IND for C-1101, a platelet-derived biologic delivered via single epidural injection, enabling U.S. expansion of a Phase I trial targeting chronic sciatica.
Bristol Myers Squibb is deploying Nvidia's DGX SuperPOD with Vera Rubin NVL72 systems to build what it claims is the most powerful AI computing infrastructure in life sciences.
Robert Allen, Ph.D., Chief Scientific Officer, outlines how the company's Invymab platform uses viral surveillance and predictive modeling to design monoclonal antibodies against likely future variants rather than current strains.
Gerren McHam, vice president of Government and External Affairs, API Innovation Center, breaks down how China's new export control regulations expose drugmakers to operational risks that have yet to draw significant industry attention.
Nuvation CEO David Hung discusses his leadership style, success stories for building camaraderie, and his inspiration for joining the pharma and biotech industry.
In today's Pharmaceutical Executive Daily, FDA converts Fabhalta's accelerated approval to full approval for IgA nephropathy, a Pharmaceutical Executive commentary argues AI-driven patient support still can't replace human connection, and Jasper Therapeutics closes its acquisition of Kira Pharmaceuticals in a deal combining a three-asset immunology pipeline.
FDA has converted Fabhalta's accelerated approval to a traditional approval for IgA nephropathy after confirmatory Phase III data showed the oral complement inhibitor slowed annual kidney function decline.
Jasper Therapeutics has closed its all-stock acquisition of Kira Pharmaceuticals and raised $132 million in concurrent financing, combining a three-asset immunology pipeline.
AI can generate words that sound like empathy, but it cannot offer the understanding that a real person can.
David Hung, CEO of Nuvation Bio, details the company’s ongoing trials for new drugs and new indications for existing molecules.
In today's Pharmaceutical Executive Daily, FDA approves Merck's Lipfendra as the first oral PCSK9 inhibitor for high cholesterol, Eli Lilly agrees to acquire AtaiBeckley for up to $3.8 billion, and a Pharmaceutical Executive podcast explores how better questions, not just more data, define strong biopharma leadership.
FDA has approved Merck's Lipfendra as the first oral PCSK9 inhibitor, giving patients with high LDL cholesterol a once-daily pill alternative to injectable therapies.
Ken Banta and Craig Tooman on why the best leaders win by asking better questions — not just chasing more data — and what that means for drug development, funding and AI in the years ahead.
Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion, adding a pipeline of neuroplastogen-based treatments.
Nuvation’s CEO David Hung details the various cancer medications the company has on the market and in clinical trials.
In today's Pharmaceutical Executive Daily, Steer Bio discusses its regenerative cell therapy platform for cancer-related lymphedema, FDA approves Celcuity's Revtorpyk as the first pan-PI3K and mTORC1/2 inhibitor for advanced breast cancer, and Insilico Medicine enters a strategic alliance with Bora Pharmaceuticals worth up to $2.5 billion.
FDA has approved Celcuity's Revtorpyk as the first pan-PI3K and mTORC1/2 inhibitor, clearing it for HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation.
Insilico Medicine and Bora Pharmaceuticals entered a strategic alliance to pair Insilico's AI drug discovery platform with Bora's development and manufacturing infrastructure.
David Hung, CEO of Nuvation Bio, explains the company’s current focus on US operations and how it utilizes partners for global impact.
As part of our continuing coverage from the BIO International Convention 2026, Pharmaceutical Executive spoke with Martha Fowler, founder of Steer Bio, about the company's regenerative medicine platform, its lead program for cancer-related lymphedema, and how non-dilutive funding is supporting its path toward first-in-human studies.
In today's Pharmaceutical Executive Daily, AstraZeneca acquires global rights to Dizal Pharmaceutical's lung cancer drug Zegfrovy in a deal worth up to $1.5 billion, FDA approves a subcutaneous formulation of Leqembi for early Alzheimer's disease, and a pharmacy executive weighs in on the education gap facing patients starting GLP-1 therapies.
AstraZeneca acquires global rights to approved EGFR exon 20 inhibitor Zegfrovy, Chai Discovery strikes an undisclosed AI antibody collaboration with Novartis, and Innovent Biologics licenses its CD40L antibody IBI355 to Spero Therapeutics.
FDA has approved a subcutaneous formulation of Leqembi, giving early Alzheimer's patients the option to self-administer the anti-amyloid therapy at home via weekly autoinjector.
Nuvation Bio’s CEO David Hung discusses the how Nuvation built a relatiohsip with Daichii Sankyo.
RedSail Technologies’ vp of clinical services discusses awareness and education gaps in how patients understand GLP-1s.
In today's Pharmaceutical Executive Daily, a new industry analysis warns that direct-to-patient pharma platforms are scaling faster than the safety infrastructure needed to support them, FDA issues a complete response letter to Elevar Therapeutics over manufacturing deficiencies in its liver cancer combination therapy, and Insilico Medicine deepens its partnership with China Medical System Holdings in a new AI-powered drug discovery collaboration worth up to $177 million.
David Hung, Nuvation Bio’s CEO, explains the company’s focus on providing patients with better drugs.
Insilico Medicine has deepened its partnership with China Medical System Holdings with a second CNS-focused collaboration in three months, pairing Insilico's PandaOmics-identified mechanism with CMS's clinical and commercial infrastructure in a deal worth up to $177 million in milestones.
FDA issued a complete response letter to Elevar Therapeutics for its rivoceranib and camrelizumab combination in first-line hepatocellular carcinoma, rejecting the application over manufacturing deficiencies rather than clinical concerns.
